Related Experiment Video
Updated: May 10, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
Polymyxins: wisdom does not always come with age
Zahra Kassamali1, John C Rotschafer, Ronald N Jones
1Department of Pharmacy Practice, University of Illinois-Chicago, 833 S. Wood St., Chicago, IL 60612, USA.
Abstract:
We currently face a lack of new antimicrobial therapies in an era of increasingly common multidrug-resistant (MDR) bacteria. The polymyxins have become last-line treatments for patients with MDR bacterial infections. An increasing body of published literature has attempted to answer questions about dosing, pharmacology, and susceptibility testing of these drugs, yet each takes for granted purity and potency of the 2 available polymyxin products. In the case of polymyxin B, true potency may vary by as much as 40% from the content reported in prescribing information. This poor accuracy is related to quality assurance assays established in the 1940s and currently in use, which have been shown to be significantly flawed in recent investigations. This review discusses the limitations of pharmacological knowledge about polymyxin antimicrobials, the clinical impact of these limitations, and suggestions for further study of these drugs in order to optimize their use clinically.
Insights
Polymyxin B potency can vary significantly due to outdated quality control assays, impacting its effectiveness against multidrug-resistant bacteria. Further research is needed to ensure accurate dosing and optimize clinical use of these critical last-line antibiotics.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- The rise of multidrug-resistant (MDR) bacteria necessitates effective last-line treatments.
- Polymyxins are crucial last-line agents for MDR bacterial infections.
- Existing literature often assumes accurate polymyxin product purity and potency.
Purpose of the Study:
- To review limitations in pharmacological knowledge of polymyxin antimicrobials.
- To discuss the clinical impact of these limitations.
- To suggest future research for optimizing polymyxin clinical use.
Main Methods:
- Literature review focusing on polymyxin pharmacology, purity, and potency.
- Analysis of quality assurance assay limitations.
- Discussion of clinical implications.
Main Results:
- Polymyxin B potency can deviate up to 40% from reported values.
- Current quality assurance assays, established in the 1940s, are flawed.
- Inaccurate potency affects reliable dosing and clinical outcomes.
Conclusions:
- Outdated and flawed quality control assays compromise polymyxin B accuracy.
- Significant gaps exist in our understanding of polymyxin pharmacology.
- Further investigation is essential to ensure optimal clinical application of polymyxins.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age
